Gamida Cell LtdOTC Pink - Current Information:GMDAQ
- LAST PRICE0.0150
- TODAY'S CHANGE (%)-0.0010 (-6.2500%)
- Bid / Lots0.0150/ 1,078
- Ask / Lots0.0188/ 266
- Open / Previous Close0.0160 / 0.0160
- Day Range
- 52 Week Range
- Volume132,262
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GMDAQ |
|---|---|---|
| 09:32 ET | 121 | 0.016 |
| 09:34 ET | 5808 | 0.016 |
| 09:38 ET | 2500 | 0.016 |
| 09:41 ET | 1250 | 0.016 |
| 09:43 ET | 10900 | 0.016 |
| 09:59 ET | 200 | 0.016 |
| 10:03 ET | 16556 | 0.01768 |
| 10:26 ET | 26133 | 0.016 |
| 10:35 ET | 842 | 0.0155 |
| 10:50 ET | 100 | 0.015 |
| 10:53 ET | 100 | 0.015 |
| 11:06 ET | 1322 | 0.015 |
| 11:18 ET | 3652 | 0.0155 |
| 11:26 ET | 424 | 0.015 |
| 11:27 ET | 20000 | 0.0155 |
| 11:36 ET | 32328 | 0.015 |
| 11:47 ET | 100 | 0.015 |
| 12:00 ET | 700 | 0.015 |
| 12:05 ET | 2587 | 0.015 |
| 12:07 ET | 149 | 0.015 |
| 12:12 ET | 5228 | 0.015 |
Apr 8, 2024
*DJ News On Gamida Cell Ltd. (GMDA) Now Under GMDAQ, from 5:08PM ET on Monday Apr 08, 2024 by Dow Jones
5:08PM ET on Monday Apr 08, 2024 by Dow JonesXORTX Welcomes New Member to the Board of Directors, from 7:30AM ET on Monday Apr 08, 2024 by Dow Jones
7:30AM ET on Monday Apr 08, 2024 by Dow Jones
Apr 1, 2024
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive, from 8:00AM ET on Monday Apr 01, 2024 by Dow Jones
8:00AM ET on Monday Apr 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Gamida Cell Ltd | 2.5M | 0.0x | --- |
Cannabis Global, Inc. | 746.4K | 0.0x | --- |
Acura Pharmaceuticals Inc | 660.0K | -0.5x | --- |
Ensysce Biosciences Inc | 1.9M | -0.1x | --- |
Genocea Biosciences Inc | 60.0 | 0.0x | --- |
Drazcanna Inc | 1.5M | -0.2x | --- |
Company Information
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.
Contact Information
- Headquarters
- PO Box 34670JERUSALEM, Israel 91340
- Phone
- ---
- Fax
- ---
Executives
- Independent Non-Executive Chairwoman of the Board
- Shawn Tomasello
- President, Chief Executive Officer, Director
- Abigail Jenkins
- Chief Financial Officer
- Terry Coelho
- Chief Scientific Officer
- Tracey Lodie
- Chief Compliance Officer, General Counsel
- Josh Patterson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.5M |
|---|---|
Revenue (TTM) | $1.8M |
Shares Outstanding | 154.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.10 |
EPS | $-0.66 |
Book Value | $-0.02 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 1.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -4,094.06% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
